Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEST trial of niraparib versus placebo after curative-intent treatment for ctDNA-positive breast cancer
MOH_2021-11-16_010406Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of niraparib in breast cancer, triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer (4 cohorts), sponsored by GSK. Started Sep 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on MOH_2021-11-16_010406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-16_010406.